Synaptogenix, Inc. (SNPX)

Last Closing Price: 0.82 (2023-06-02)

Company Description

Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-5.57M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.19
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -13.39%
Return on Assets (Trailing 12 Months) -12.14%
Current Ratio (Most Recent Fiscal Quarter) 28.59
Quick Ratio (Most Recent Fiscal Quarter) 28.59
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $4.50
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $-2.06
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 7.36M
Free Float 6.77M
Market Capitalization $6.04M
Average Volume (Last 20 Days) 0.06M
Beta (Past 60 Months) 1.26
Percentage Held By Insiders (Latest Annual Proxy Report) 7.95%
Percentage Held By Institutions (Latest 13F Reports) 6.99%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%